Novo Nordisk receives FDA approval for Sogroya in three new pediatric indications
📌 Key Takeaways
- {"type":"skipped","reason":"older_than_6_hours"}
📚 Related People & Topics
Novo Nordisk
Danish pharmaceutical company
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S (wholly owned by the Novo Nordisk Foundation) which holds approximately 28.1% of its shares and a majority (77.1%) of its voting shares. N...
Entity Intersection Graph
Connections for Novo Nordisk:
🌐
Semaglutide
8 shared
👤
Eli Lilly
5 shared
🌐
Hims
2 shared
🏢
Food and Drug Administration
2 shared
🌐
India
2 shared
Mentioned Entities
Original Source
Investing.com -- Novo Nordisk announced late Friday that the US Food and Drug Administration has approved three new indications for once-weekly Sogroya (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg, a long-acting growth hormone.
Read full article at source